Hutchmed (China) Limited Stock Price, News & Analysis

HUTCHMED (Nasdaq/AIM: HCM) has launched two international Phase I trials for HMPL-306, a dual inhibitor targeting IDH1 and IDH2 mutations in advanced solid tumors and hematological malignancies. The trials, initiated on March 25, 2021, follow a prior study in China. Each trial will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy. This marks HMPL-306 as HUTCHMED's sixth drug candidate in global clinical development, showcasing its expanding clinical presence.

HUTCHMED announced an agreement to sell its indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited for approximately $169 million. This sale enables HUTCHMED to focus on clinical development and market launches of its oncology and immunology assets. The cash received from this transaction is about 22 times HBYS' adjusted net profit of $7.7 million in 2020. The deal is subject to regulatory approval in China and is expected to close in mid-2021.

HUTCHMED has launched a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab targeting advanced solid tumors in the U.S. and Europe. The first patient was dosed on March 23, 2021. This study aims to assess the drug combination's safety, tolerability, pharmacokinetics, and efficacy. It comprises two parts: Part 1 focuses on determining the recommended Phase II dose and/or maximum tolerated dose, while Part 2 evaluates antitumor activity in specific cancers, including neuroendocrine tumors and colorectal cancer. Details are available at clinicaltrials.gov (NCT04579757).

Hutchison China MediTech Limited (HUTCHMED) announced its 2020 financial results and updates on clinical developments. For 2021, they forecast consolidated revenues of $110-130 million, significantly up from $30.2 million in 2020. The company has expanded its oncology operations and achieved a 91% increase in sales of ELUNATE®. SULANDA® was launched in January 2021, generating $4.9 million in its first two months. The company seeks shareholder approval for a name change to HUTCHMED (China) Limited at the upcoming AGM. The net loss attributable to HUTCHMED for 2020 was $125.7 million, slightly above the $106.0 million loss in 2019.

Hutchison China MediTech Limited (HCM) will announce its final results for the fiscal year ending December 31, 2020, on March 4, 2021. The announcement will take place at 12:00 noon GMT, with a conference call and audio webcast scheduled for 1:00 pm GMT. Chi-Med is a biopharmaceutical company focused on the development of targeted therapies and immunotherapies for cancer and immunological diseases, boasting a portfolio of nine clinical drug candidates and a strong presence in China.

Hutchison China MediTech Limited (HCM) announced promising results from the Phase III SANET-p trial for surufatinib, a treatment for advanced pancreatic neuroendocrine tumors (NET). The study demonstrated a 51% reduction in the risk of disease progression or death compared to placebo. Median progression-free survival (PFS) was 10.9 months with surufatinib versus 3.7 months for placebo. Positive results were complemented by findings from the SANET-ep trial. The safety profile of surufatinib was manageable, with discontinuation rates of 10.6% for the treatment group.

Hutchison China MediTech Limited (HCM) announced that its New Drug Application for surufatinib, aimed at treating advanced pancreatic neuroendocrine tumors (NET), has been accepted by the China National Medical Products Administration (NMPA). The submission is supported by data from the successful SANET-p study, which demonstrated improved progression-free survival. Surufatinib has also received Fast Track Designation status from the FDA for both pancreatic and non-pancreatic NET. Chi-Med retains all global rights to surufatinib.

Hutchison China MediTech Limited (HCM) has commenced the Phase III FRESCO-2 study of fruquintinib for metastatic colorectal cancer, starting with the first patient dosed on September 3, 2020. This global trial will enroll around 130 sites across 10 countries, aiming for overall survival as the primary endpoint. The FDA previously granted Fast Track Designation for fruquintinib for this indication, with results from prior studies aiding a future New Drug Application. Fruquintinib, already marketed in China, targets VEGFR and shows promise for combining with other therapies.

Chi-Med (Nasdaq/AIM: HCM) has commenced a Phase II clinical study of HMPL-453, a selective inhibitor targeting FGFR in patients with advanced intrahepatic cholangiocarcinoma (IHCC). This single-arm, open-label study aims to assess the drug's efficacy and safety in patients with FGFR2 fusion who have not responded to prior treatments. Key metrics include objective response rate and survival rates. IHCC represents a significant health challenge, particularly in China, where it accounts for 10-20% of liver cancers. The global incidence of liver cancer was over 390,000 cases in 2018, highlighting the need for effective therapies.